Clinical Trial

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-07
Trial Details
NCT Number NCT07418749
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Recurrent Cervical Cancer, Metastatic Cervical Cancer
Enrollment 398 participants
Start Date 2026-03-30
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-06